News & Updates

Results of the phase III ASSURE study support seladelpar – a novel first-in-class delpar (selective peroxisome proliferator-activated receptor delta agonist) – for the treatment of primary biliary cholangitis (PBC).

Young adults with metabolic dysfunction-associated steatotic liver disease (MASLD) who drink alcoholic beverages are at greater risk of mortality and of having an unhealthy liver, reports a study presented at AASLD 2024.